文献速递呼吸道感染呼吸危重症与机械通气

静脉注射免疫球蛋白治疗COVID-19相关中重度ARDS的多中心双盲安慰剂对照3期试验

Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2021-11-11

在法国43个中心开展的多中心、双盲、安慰剂对照3期试验,纳入146例PCR确诊COVID-19并接受有创机械通气≤72小时的中重度ARDS患者,随机接受IVIG(2 g/kg,4天)或安慰剂。结果显示第28天无机械通气天数无统计学差异,IVIG组严重不良事件有增多趋势但未达显著,提示IVIG未改善临床结局。

要点

  • COVID-19相关中重度ARDS接受有创机械通气患者中,IVIG未改善第28天无机械通气天数。
  • 研究提示IVIG对COVID-19相关中重度ARDS无获益,未来可评估其在疾病早期阶段的作用。

核心结论

  • 在COVID-19相关中重度ARDS接受有创机械通气的患者中,IVIG未改善第28天无机械通气天数,且严重不良事件有增多趋势但未达显著。
  • 研究提示IVIG对COVID-19相关中重度ARDS无临床获益,未来应评估其对COVID-19早期阶段的作用。

研究设计与样本

  • 多中心、双盲、安慰剂对照3期试验,在法国43个中心开展。
  • 纳入PCR确诊COVID-19并接受有创机械通气≤72小时、合并中重度ARDS的患者,按1:1随机分配至IVIG组或安慰剂组。
  • 随机化按参与中心及入组前有创机械通气时长(<12小时、12-24小时、>24-72小时)分层,治疗在开始有创机械通气后96小时内给予。
  • 主要结局为第28天无机械通气天数,按意向性治疗原则分析;共146例患者被随机分配(IVIG组69例,安慰剂组77例)。

临床怎么用

  • 对于COVID-19相关中重度ARDS接受有创机械通气的患者,不推荐常规使用IVIG以期改善第28天无机械通气天数。
  • 使用IVIG时需关注严重不良事件风险,本研究显示其发生频率有增多趋势但未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute respiratory distress syndrome (ARDS) is a major complication of COVID-19 and is associated with high mortality and morbidity. We aimed to assess whether intravenous immunoglobulins (IVIG) could improve outcomes by reducing inflammation-mediated lung injury. METHODS: In this multicentre, double-blind, placebo-controlled trial, done at 43 centres in France, we randomly assigned patients (1:1) receiving invasive mechanical ventilation for up to 72 h with PCR confirmed COVID-19 and associated moderate-to-severe ARDS to receive either IVIG (2 g/kg over 4 days) or placebo. Random assignment was done with a web-based system and was stratified according to the participating centre and the duration of invasive mechanical ventilation before inclusion in the trial (<12 h, 12-24 h, and >24-72 h), and treatment was administered within the first 96 h of invasive mechanical ventilation. To minimise the risk of adverse events, the IVIG administration was divided into four perfusions of 0·5 g/kg each administered over at least 8 hours. Patients in the placebo group received an equivalent volume of sodium chloride 0·9% (10 mL/kg) over the same period. The primary outcome was the number of ventilation-free days by day 28, assessed according to the intention-to-treat principle. This trial was registered on ClinicalTrials.gov, NCT04350580. FINDINGS: Between April 3, and October 20, 2020, 146 patients (43 [29%] women) were eligible for inclusion and randomly assigned: 69 (47%) patients to the IVIG group and 77 (53%) to the placebo group. The intention-to-treat analysis showed no statistical difference in the median number of ventilation-free days at day 28 between the IVIG group (0·0 [IQR 0·0-8·0]) and the placebo group (0·0 [0·0-6·0]; difference estimate 0·0 [0·0-0·0]; p=0·21). Serious adverse events were more frequent in the IVIG group (78 events in 22 [32%] patients) than in the placebo group (47 events in 15 [20%] patients; p=0·089). INTERPRETATION: In patients with COVID-19 who received invasive mechanical ventilation for moderate-to-severe ARDS, IVIG did not improve clinical outcomes at day 28 and tended to be associated with an increased frequency of serious adverse events, although not significant. The effect of IVIGs on earlier disease stages of COVID-19 should be assessed in future trials. FUNDING: Programme Hospitalier de Recherche Clinique.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Mazeraud A, Jamme M, Mancusi RL, et al. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021. PMID: 34774185. doi:10.1016/S2213-2600(21)00440-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。